Financing channel feed – Endpoints News

Financing channel feed

Looking to take advantage of 'silenced' enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

5 years ago

Perceptive's fourth — yes, fourth — SPAC jumps to Nasdaq as the blank check tree continues to ripen

5 years ago

NK cell therapy player Artiva makes some more noise, pulling in $120M Series B less than a month after Merck deal

5 years ago

In search of 'household healthcare brands of the future,' Foresite Capital raises $969M to satiate a tech-heavy appetite

5 years ago

Flagship upstart Cellarity gathers $123M to finance its exploration of cell behavior, blazing a new path to building a broad pipeline

5 years ago

Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds

5 years ago

Jeff Hatfield assembles a syndicate with some A-list public investors in the mix as Vividion adds $135M raise

5 years ago

Japan's SoftBank plots billions in biotech investments in move that could keep the valuation flood rising — report

5 years ago

Six years separated from a rabies vaccine scandal, China’s YishengBio grabs $130M to go big in infectious diseases, cancer

5 years ago

Fueled by Covid prospects, Chinese vaccine developer scores $230M to upscale the whole pipeline

5 years ago

After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard

5 years ago

Is biotech the new bitcoin? A top analyst draws some uncomfortable comparisons to a certain cryptocurrency as 'biotech mania' flourishes

5 years ago

The $1M IPO bonus, decent pay and a nice equity stake to mark the upside: How does Mark McKenna's comp package stack up in the Nasdaq rush?

5 years ago

Old-hat investors Alta Partners snag $275M for their newest next-gen fund, more than double the first iteration from 2018

5 years ago

The SPAC boom continues to churn out heavy capital, as Foresite prices its $175M blank check company and 2 others file

5 years ago

Amid the 'superbug' crisis, a Big Pharma-backed fund scores a meager raise for antibiotics R&D. Is $140M nearly enough?

5 years ago

Royalty Pharma gets more competition as a private equity firm launches $725M royalty-buying fund

5 years ago

Eduardo Bravo returns to bring European biotech in on the SPAC splurge

5 years ago

VC style returns on 'unsexy' public health bets? Gates-backed Adjuvant Capital gathers $300M to mend a 'failure of imagination'

5 years ago

Advent Life Sciences launches two funds totaling $215M, and teams with Harrington Discovery Institute to translate research

5 years ago

A step behind its major exosome challenger, Evox scores $95M round for final leg of race to the clinic

5 years ago

SpyBiotech cashes in on Serum Institute deal, netting $32.5M round for its 'superglue' VLP vaccine tech

5 years ago

Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup

5 years ago

GlaxoSmithKline bets another $345M cash on Vir, expanding Covid-19 partnership to flu, RSV and other viruses

5 years ago

First page Previous page 81 82 838485 86 87 Next page Last page